Log in to search using one of your social media accounts:

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B
In case you missed it, theAtlanta Journal-Constitution analyzed data on hospital participation in the 340B program in Georgia and found that some hospitals are raking in huge profits – with no benefit to patients. (Source: The Catalyst)
Source: The Catalyst - June 20, 2017 Category: Pharmaceuticals Tags: 340B hospitals 340B Spotlight Source Type: news

Medicare Monday: How government price setting in Part D could reduce innovation, shorten life expectancy for beneficiaries
Today, we are diving into the conversation about how government price setting proposals could impact the Medicare Part D program and beneficiaries. Imposing Veterans Administration (VA)-style pricing in the Part D program has been suggested as a way to lower costs. However, arecent study found that imposing VA-style pricing in Part D would have significant, negative long-term implications for patients. (Source: The Catalyst)
Source: The Catalyst - June 19, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

In the OECD other health care services will be ten times prescription medicine spending growth over next decade
Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening diseases.  In the midst of this medical progress, other health care expenditures such as inpatient care, long-term care and administration, have grown much faster than prescription medicine expenditures. Across OECD countries, other health care services will grow by $23.5 trillion over the next decade, compared to $2.2 trillion for prescription medicines. (Source: The Catalyst)
Source: The Catalyst - June 14, 2017 Category: Pharmaceuticals Authors: Kevin Haninger Tags: Value drug cost health care spending Source Type: news

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority
Yesterday, PhRMA filedcomments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration ’s review of our trading relationship with Mexico and Canada serves as a critical point in time for the U.S. to seek to resolve a number of outstanding issues stemming from weak enforcement of existing intellectual property (IP) commitments, and price-setting measures being considered by our tradi ng partners, under NAFTA and other international obligations. (Source: The Catalyst)
Source: The Catalyst - June 13, 2017 Category: Pharmaceuticals Tags: Intellectual Property trade Source Type: news

Examining the brain in The New Era of Medicine
Biopharmaceutical innovation is powering a rapid pace of medical breakthroughs and scientific advancements. America ’s biopharmaceutical companies are working day in and day out to uncover new targets, treatments and ultimately cures for patients’ lives. (Source: The Catalyst)
Source: The Catalyst - June 13, 2017 Category: Pharmaceuticals Tags: biomarkers New Era of Medicine GoBoldly Source Type: news

Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
We ’ve seen significant progress in recent years in the treatment of cancer, and that progress is expected to continue. Anew report released this month found that there are more than 240 new immuno-oncology treatments in development – treatments designed to enable the patient’s own immune system to fight cancer.  (Source: The Catalyst)
Source: The Catalyst - June 12, 2017 Category: Pharmaceuticals Tags: Medicines in Development cancer Medicare Medicare Monday Part B Source Type: news

Fact Check Friday: The truth about IPAB
This week on Fact Check Friday, we ’re taking a closer look at the Independent Payment Advisory Board (IPAB) – the panel tasked with proposing cuts to Medicare if spending exceeds a certain growth target. (Source: The Catalyst)
Source: The Catalyst - June 9, 2017 Category: Pharmaceuticals Tags: Medicare IPAB Fact Check Source Type: news

Modernizing FDA regulations to advance a value-driven health care system
A modern regulatory framework is the foundation of an innovative health care system that allows stakeholders to work together to deliver better outcomes for patients. To advance critical regulations toward this end, the U.S. Food and Drug Administration (FDA) announced last September that it would engage in a comprehensive review of its rules governing biopharmaceutical company communications related to unapproved uses of approved medicines. The FDA also sought input on this from key stakeholders over a two-day public hearing late last fall. (Source: The Catalyst)
Source: The Catalyst - June 8, 2017 Category: Pharmaceuticals Tags: Value-Driven Health Care GoBoldly Source Type: news

Opening the conversation around mental health treatment with advocates & industry leaders
Biopharmaceutical research and innovation is making strides in the world of mental health by expanding the understanding of the field and bringing about a new era of mental health medicine. No longer are mental health treatments being created just for patients, but they are being created with the help and guidanceof patients. (Source: The Catalyst)
Source: The Catalyst - June 6, 2017 Category: Pharmaceuticals Tags: Mental Health Source Type: news

Foreign government price setting by any name harms innovation and access to medicines
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below thevalue they provide to patients, health care systems, and the wider economy. By distorting market competition, these short-sighted measures domore harm than good, and fail to address the root causes of rising health care costs such as increased rates of chronic disease. Whilegovernment price setting can take several different forms, all deliver the same troubling results – stifled innovation and reduced access to quality health care for patients around the world. (Source: The Catalyst)
Source: The Catalyst - June 6, 2017 Category: Pharmaceuticals Authors: Kevin Haninger Tags: Access Intellectual Property trade Source Type: news

Medicare Monday: Positive impact of Part D on America ’s seniors
Implementation of Medicare Part D significantly increased access to medicines for seniors and for those under age 65 with permanent disabilities. Since then, Part D has contributed to significant reductions in medication nonadherence and hospitalization, which has led to improved health and life expectancy among America ’s seniors. Today, we’re looking at these improvements and how they have positively impacted beneficiaries. (Source: The Catalyst)
Source: The Catalyst - June 5, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Medication Adherence Source Type: news

PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
  The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published on Forbeshereon June 2, 2017.The way our health care system currently pays for prescription medicines is convoluted and confusing. We rely on a complicated system of list prices, net prices, rebates and an opaque supply chain that often results in uncertainty and frustration for patients. It is no wonder consumers and policymakers have questions and are looking for better answers. So are we. (Source: The Catalyst)
Source: The Catalyst - June 2, 2017 Category: Pharmaceuticals Tags: The Value Collaborative Source Type: news

A critical opportunity to prevent prescription drug abuse
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently cited addressing the opioid crisis as his highest priority. As someone who has spent the bulk of my career focused on issues related to substance abuse, including more than 10 years with PhRMA and prior to that almost 8 years in the White House Drug Policy Office, I am heartened to see the FDA commit to helping solving this problem. The abuse of prescription opioids, counterfeit opioids and heroin has resulted in a deepening public health crisis. This has impacted individuals and their loved ones, our first responders who are on the front lines an...
Source: The Catalyst - June 2, 2017 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: FDA Prescription Drug Safety Policy Solutions Medication Adherence Source Type: news

Celebrating PRIDE in biopharmaceutical science
Today marks the beginning of Lesbian, Gay, Bisexual, and Transgender (LGBT) Pride Month and we are proud to join with our member companies in celebrating our support for the LGBT community. We recognize that inclusion and diversity fuels collaboration, trust to make the next leap into biomedical research and fosters an openness to tackling old problems with new ideas. (Source: The Catalyst)
Source: The Catalyst - June 1, 2017 Category: Pharmaceuticals Tags: PhRMA Member Company Source Type: news

More than 240 immuno-oncology treatments in development to fight cancer
The American Cancer Society estimates that in 2017 alone, there will be more than 1.6 million new cases of cancer and 600,000 cancer deaths in the United States. With estimates like these, the need for new cancer treatments is more important than ever, and America ’s biopharmaceutical companies are boldly leading the way in discovering new breakthroughs. (Source: The Catalyst)
Source: The Catalyst - June 1, 2017 Category: Pharmaceuticals Tags: Medicines in Development Personalized Medicine cancer Source Type: news

ICYMI: Avalere and FasterCures develop new value framework from patient perspective
In case you missed it, a year-long collaboration between Avalere and FasterCures has resulted in the first value framework from the patient perspective. Unlike other frameworks which include limited input from patients or other stakeholders, thePatient-Perspective Value Framework (PPVF) initiativewas a true collaboration led by a steering committee of 23 organizations, including the Centers for Medicare& Medicaid Services (CMS). The steering committee took into consideration input from 270 people and organizations across the health care system in the form of targeted surveys, focus groups and roundtable discussions. No...
Source: The Catalyst - May 31, 2017 Category: Pharmaceuticals Tags: Value-Driven Health Care GoBoldly Source Type: news

Fighting multiple sclerosis: New Together ad illuminates the journey of patient & scientist
Meet Laurel and Ian. Laurel is a patient living with multiple sclerosis (MS), and Ian is a scientist developing new treatments to help Laurel and the other 2.3 million people with MS live longer, healthier lives. Their emotional stories are the latest advertisement from the GOBOLDLY™ campaign as part of the Togetherseries, which features the stories of researchers behind cutting-edge breakthroughs alongside patients battling serious disease and chronic illness with the help of biopharmaceutical innovation. (Source: The Catalyst)
Source: The Catalyst - May 31, 2017 Category: Pharmaceuticals Tags: GoBoldly Source Type: news

Medicare Monday: Catch up on MedPAC and its Part B recommendations
A long weekend is the perfect time to catch up on your reading list. For policy wonks, you can get up to speed with our Memorial Day reading list on the Medicare Payment Advisory Commission (MedPAC), how it informs Medicare policy and its recent Part B recommendations, which are expected to be included in their report to Congress this June. (Source: The Catalyst)
Source: The Catalyst - May 29, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

Medicines have significantly increased chances of cancer survival around the globe
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies.According to the CDC, for patients with childhood leukemia, prostate, and breast cancers, five-year survival has increased steadily in most developed countries, with some countries reporting five-year survival rates of more than 85%.   (Source: The Catalyst)
Source: The Catalyst - May 24, 2017 Category: Pharmaceuticals Authors: Amey Sutkowski Tags: Research and Development Value cancer drug cost Source Type: news

Administration ’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation
In the latest publication of its annualSpecial 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges in overseas markets that are harming American innovators, patients, and workers.PhRMA is encouraged by the Administration ’s emphasis on the importance of enforcing obligations in existing trade agreements and bilateral discussions. We view the report as a potential basis for engaging trading partners to more effectively address negative practices and regain a level-playing field for American companies – particular ly th...
Source: The Catalyst - May 23, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Intellectual Property 301 Report trade Source Type: news

Medicare Monday: Did you know Medicare Part B uses a market-based system to pay for medicines?
We often discuss the creation ofPart D when we talk about the market-based changes that the Medicare Modernization Act (MMA) made to Medicare, but that ’s just one example. Today, let’s take a closer look at the market-based changes that the MMA made to Medicare Part B with the creation ofAverage Sales Price (ASP). (Source: The Catalyst)
Source: The Catalyst - May 22, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

Compulsory licensing: A misused and abused international trade law
To maintain our position as the world ’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing abuse – along with price controls and other trade barriers – threatens to chip away at our foothold and erode the resources companies c an invest in the next generation of medicines. (Source: The Catalyst)
Source: The Catalyst - May 16, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Access Intellectual Property trade Source Type: news

Medicare Monday: Why imposing Medicaid-style rebates in Part D is a bad idea
We ’ve talked a lot about howrepealing the non-interference clause in Medicare Part D would negatively impact beneficiaries. But there are other proposals to fundamentally alter the structure of Part D that would cause just as much harm to beneficiaries. Today, let ’s look at one: Imposing mandatory Medicaid-style rebates on low-income utilization in Part D. (Source: The Catalyst)
Source: The Catalyst - May 15, 2017 Category: Pharmaceuticals Tags: Part D Medicare Medicare Monday Source Type: news

A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
Today, we released the latest chapter of GOBOLDLY™ advertising titledNew World, featuring the extraordinary breakthroughs in science being discovered by biopharmaceutical researchers. (Source: The Catalyst)
Source: The Catalyst - May 15, 2017 Category: Pharmaceuticals Tags: New Era of Medicine GoBoldly Source Type: news

ICYMI: New study shows medicines advance life expectancy for HIV patients
In the three decades since the HIV/AIDS crisis first struck the United States, incredible strides have been made in understanding and treating this disease. (Source: The Catalyst)
Source: The Catalyst - May 15, 2017 Category: Pharmaceuticals Tags: HIV/AIDS Source Type: news

Former law enforcement officials raise concerns with drug importation proposals
Time and again, proponents of drug importation schemes overlook the major impact such proposals would have on our law enforcement officers – the men and women who spend their lives protecting Americans and protecting our borders. And the reality is, allowing drug importation would greatlyincrease the burden on our already overextended law enforcement agencies. (Source: The Catalyst)
Source: The Catalyst - May 11, 2017 Category: Pharmaceuticals Tags: Safety Counterfeit Drugs Imported Drugs Source Type: news

Why won ’t the insurance industry tell the truth about medicine costs?
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care stakeholders to advance commonsense solutions that will bring down costs and improve affordability for patients. But in order to have an honest conversation about this important issue, we need to have agreement on the facts. Unfortunately, the insurance industry is continuing to advance a false and misleading narrative about prescription medicine cost growth. (Source: The Catalyst)
Source: The Catalyst - May 10, 2017 Category: Pharmaceuticals Tags: drug cost out of pocket costs health care spending Pharmacy Benefit Managers Source Type: news

Government-imposed price controls threaten innovation and access
It ’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any other country – and support 4.5 million jobs nationwide. (Source: The Catalyst)
Source: The Catalyst - May 9, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Access Intellectual Property trade Source Type: news

Medicare Monday: How finding an Alzheimer ’s treatment could lower Medicare spending
Alzheimer ’s disease is devastating and impacts more than 5.5 million Americans and their families. While America’s biopharmaceutical researchers have been working tirelessly to find a cure for the disease, there is still a long way to go to ease the burden on patients and the health care system. (Source: The Catalyst)
Source: The Catalyst - May 8, 2017 Category: Pharmaceuticals Tags: Alzheimer's Medicare Medicare Monday Source Type: news

ICYMI: Innovative payment models helping provide patient access to new medicines
As we continue to make remarkable strides to treat our most costly and challenging diseases, there is a renewed focus on ensuring patients have access to the most innovative medicines. Increasingly, biopharmaceutical companies are entering into value-based contracts with payers  – such as payment models that link reimbursement to patient outcomes. By doing so, payers and biopharmaceutical companies are working together to control costs and provide patients access to new, life-saving treatments.  (Source: The Catalyst)
Source: The Catalyst - May 5, 2017 Category: Pharmaceuticals Tags: The Value Collaborative Source Type: news

Guest Post: The Clinical trial experience from a patient & researcher perspective
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. (Source: The Catalyst)
Source: The Catalyst - May 5, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Clinical Trials Source Type: news

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
America ’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property protections, public sector investments in education and basic sciences, and a reliable rule of law. However, as PhRMA President and CEOSteven J. Ubl notes in Real Clear Health, other countries put up trade-related barriers that weaken U.S. competitors and benefit their own domestic industries. (Source: The Catalyst)
Source: The Catalyst - May 5, 2017 Category: Pharmaceuticals Tags: Patents Intellectual Property trade Source Type: news

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report
We have seen adeluge of data recently from government actuaries and pharmacy benefit managers showing a dramatic slowdown in medicine spending growth.And theQuintilesIMS Medicines Use and Spending in the U.S. — A Review of 2016 and Outlook to 2021report further supports this data. (Source: The Catalyst)
Source: The Catalyst - May 4, 2017 Category: Pharmaceuticals Tags: drug cost health care spending Source Type: news

Guest Post: Patients as research partners - Rethinking patient access to clinical trial data
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post from Janssen ’s Andreas Koester, M.D., Ph.D., Vice President, Innovation, Janssen Research& Development Operations. (Source: The Catalyst)
Source: The Catalyst - May 4, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Clinical Trials Source Type: news

Guest Post: Spotlighting the heroes in clinical trials
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.We are pleased to share a blog post from Eli Lilly and Company in celebration of Clinical Trials Awareness Week. The post was originally featured atLillyPad. (Source: The Catalyst)
Source: The Catalyst - May 3, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Clinical Trials Source Type: news

Guest Post: Advancing oncology research through clinical trials
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.In celebration of Clinical Trials Awareness Week, we are pleased to share a blog postthat was written by Eric Rubin, M.D., medical oncologist and vice president, Global Clinical Onc...
Source: The Catalyst - May 2, 2017 Category: Pharmaceuticals Authors: Guest Contributor Tags: Clinical Trials Source Type: news

Illegal trade barriers discriminate against U.S. innovators
America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American workers. But to ensure the industry continues to deliver these benefits, the U.S. needs a level playing field when it comes to international trade. (Source: The Catalyst)
Source: The Catalyst - May 2, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Patents Intellectual Property trade Source Type: news

Clinical Trials Awareness Week: Celebrating the impact of clinical research
Today starts off the beginning of Clinical Trials Awareness Week, which shines a spotlight on how the clinical trials process helps deliver safe, effective medicines to patients. (Source: The Catalyst)
Source: The Catalyst - May 1, 2017 Category: Pharmaceuticals Tags: Clinical Trials clinical research Source Type: news

Medicare Monday: What the experts are saying about the Independent Payment Advisory Board
The Independent Payment Advisory Board (IPAB), a panel of 15 members selected by the President and confirmed by the Senate, is tasked with proposing cuts to Medicare if spending exceeds a certain growth target. If no board is appointed, IPAB ’s powers transfer automatically to the Secretary of Health and Human Services. (Source: The Catalyst)
Source: The Catalyst - May 1, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday IPAB Source Type: news

ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
As the understanding of each person ’s unique DNA makeup continues to grow (better known as genomics), personalized medicine is rapidly reaching new heights. (Source: The Catalyst)
Source: The Catalyst - April 28, 2017 Category: Pharmaceuticals Tags: Personalized Medicine New Era of Medicine GoBoldly Source Type: news

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
As we ’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in some cases. Roughly45 percent of Medicare acute care hospitals participate in 340B. Many of these hospitals have expanded their reach by buying community-based physician practices and then obtaining 340B discounts for prescriptions written by those physicians.  (Source: The Catalyst)
Source: The Catalyst - April 27, 2017 Category: Pharmaceuticals Tags: 340B hospitals 340B Spotlight Policy Solutions Market Distortions Source Type: news

A new era in genomics
Personalized medicine has taken on a new meaning with the mapping of the human genome. (Source: The Catalyst)
Source: The Catalyst - April 26, 2017 Category: Pharmaceuticals Tags: Research and Development New Era of Medicine GoBoldly Source Type: news

Australia is making it harder to protect inventions. That ’s bad for American businesses and jobs.
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow ’s breakthrough treatments and cures, innovators must be able to protect and enforce patents and other intellectual property. (Source: The Catalyst)
Source: The Catalyst - April 25, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Patents Intellectual Property trade Policy Solutions Source Type: news

Medicare Monday: Stakeholders raise concern with MedPAC ’s proposed changes to drug purchasing program
A couple weeks ago, we looked at what a broad group of stakeholders have said about the recommendedchanges to Part B that the Medicare Payment Advisory Commission (MedPAC) voted in support of. But this week, we wanted to examine one proposed change a bit more. (Source: The Catalyst)
Source: The Catalyst - April 24, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

The risks of counterfeit imported medicines
A recentWall Street Journal article laid out the serious concerns posed by potent, counterfeit prescription opioids pouring into the United States from China, Mexico and Canada. The Drug Enforcement Administration (DEA) and other U.S. law enforcement face a growing challenge in preventing counterfeit fentanyl from reaching the United States. Fentanyl is exponentially more powerful than morphine and heroin. Its use is generally limited to use in the management of breakthrough pain in cancer patients – but now hundreds of thousands of pills produced in China are illegally flowing into the United States through Canada a...
Source: The Catalyst - April 20, 2017 Category: Pharmaceuticals Tags: Counterfeit Drugs Imported Drugs Source Type: news

Fighting disease Together: New ads feature patients and the researchers behind today ’s breakthroughs
Today, we launched our next wave of advertising as part of the GOBOLDLY™ campaign, titledTogether, featuring the stories of researchers developing cutting-edge breakthroughs alongside patients fighting for their lives with the help of biopharmaceutical innovation. (Source: The Catalyst)
Source: The Catalyst - April 19, 2017 Category: Pharmaceuticals Tags: diabetes ALS Alzheimer's cancer Patients Hepatitis C heart disease New Era of Medicine GoBoldly Source Type: news

Trading fair means upholding the law: A focus on patents
Patents are the linchpin of innovation. In the United States and other countries around the world, they provide temporary protection for new inventions. A fair, stable and predictable patent system is the engine of the leading-edge U.S. biopharmaceutical industry, which produces $1.2 trillion in annual economic output and supports 4.5 million jobs across America. (Source: The Catalyst)
Source: The Catalyst - April 18, 2017 Category: Pharmaceuticals Authors: Jay Taylor Tags: Intellectual Property 301 Report trade Policy Solutions Source Type: news

Mental health in the New Era of Medicine
Research and development of innovative medicines to promote mental health are a priority for America ’s biopharmaceutical research companies. Withmore than 130 medicines in development for mental illness, biopharmaceutical scientists are making discoveries in the lab that put treatments in the hands of patients. (Source: The Catalyst)
Source: The Catalyst - April 18, 2017 Category: Pharmaceuticals Authors: Bill Chin, M.D. Tags: Mental Health GoBoldly Source Type: news

New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
In an exciting step forward to support research and development of innovative new medicines and devices for pediatric patients, the Critical Path Institute (C-Path)announced the launch of a new nonprofit to address challenges in bringing new therapies to children in need. (Source: The Catalyst)
Source: The Catalyst - April 17, 2017 Category: Pharmaceuticals Authors: Lucy Vereshchagina Tags: Patents Source Type: news

Driving innovation through collaboration
Anew report from Deloitte examines the changing landscape of biopharmaceutical research, as stakeholders across the R&D ecosystem are increasingly coming together to tackle sciences ’ most vexing health challenges. (Source: The Catalyst)
Source: The Catalyst - April 17, 2017 Category: Pharmaceuticals Tags: Research and Development clinical research case studies Source Type: news